Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (572)
All Articles published online
|
Publishing Process of This Article
|
Sep 15, 2025 (publication date) through Nov 21, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Xing YL, Li HM, Pang XM, Zhang Y, Yang T, Li YH, Liu DC, Ma YY, Niu LZ. Irreversible electroporation combined with checkpoint blockade stimulates antitumor immune response in a hepatocellular carcinoma mouse model. World J Gastrointest Oncol 2025; 17(9): 110166 [PMID: 40977659 DOI: 10.4251/wjgo.v17.i9.110166] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Xing YL, Li HM, Pang XM, Zhang Y, Yang T, Li YH, Liu DC, Ma YY, Niu LZ. Irreversible electroporation combined with checkpoint blockade stimulates antitumor immune response in a hepatocellular carcinoma mouse model. World J Gastrointest Oncol 2025; 17(9): 110166 [PMID: 40977659 DOI: 10.4251/wjgo.v17.i9.110166] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v17/i9/110166.htm |
| Number | Citing Articles |
| 1 |
Zhaojia Wu, Zhenyu Yang, Tauqeer Iftikhar, Gary Groot, Scot C. Leary, Nicolas Baniak, Shahid Ahmed, Mark Bosch, Michael Moser, Wenjun Zhang, Junhong Jiang, Jim Xiang. CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses. Cancer Immunology, Immunotherapy 2025; 74(12) doi: 10.1007/s00262-025-04217-7
|